William D. Waddill Arrowhead Pharmaceuticals, Inc. (ARWR) insider trading activity

William D. Waddill is Director of ARROWHEAD PHARMACEUTICALS, INC.. Currently has a direct ownership of 56,563 shares of ARWR, which is worth approximately $2.33 Million. The most recent transaction as insider was on Dec 19, 2025, when has been sold 8,367 shares (Common Stock) at a price of $67.73 per share, resulting in proceeds of $566,696. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 56.6K

0.96% 3M change

0.96% 12M change

Total Value Held $2.33 Million

William D. Waddill Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 19 2025	SELL Open market or private sale	$566,696 $67.73 p/Share	8,367 Reduced 12.89%	56,563 Common Stock
Dec 16 2025	BUY Grant, award, or other acquisition	-	7,819 Added 10.75%	64,930 Common Stock
Dec 18 2024	BUY Grant, award, or other acquisition	$384,691 $22.99 p/Share	16,733 Added 22.66%	57,111 Common Stock
Dec 17 2024	SELL Open market or private sale	$82,583 $22.04 p/Share	3,747 Reduced 8.49%	40,378 Common Stock
Dec 16 2024	SELL Open market or private sale	$82,081 $21.9 p/Share	3,748 Reduced 7.83%	44,125 Common Stock
Jan 11 2024	SELL Open market or private sale	$150,278 $38.2 p/Share	3,934 Reduced 7.59%	47,870 Common Stock
Dec 15 2023	BUY Grant, award, or other acquisition	$380,819 $25.41 p/Share	14,987 Added 22.44%	51,804 Common Stock

Jan 10 2023	BUY Grant, award, or other acquisition	-	7,867 Added 17.61%	36,817 Common Stock
Jan 09 2023	SELL Open market or private sale	$96,000 $30.0 p/Share	3,200 Reduced 9.95%	28,950 Common Stock
Jan 07 2022	BUY Grant, award, or other acquisition	-	6,400 Added 16.6%	32,150 Common Stock
Jan 03 2022	SELL Open market or private sale	$293,220 $65.16 p/Share	4,500 Reduced 14.88%	25,750 Common Stock
Jan 04 2021	SELL Open market or private sale	$285,300 $76.08 p/Share	3,750 Reduced 11.03%	30,250 Common Stock
Jan 01 2021	BUY Grant, award, or other acquisition	-	9,000 Added 20.93%	34,000 Common Stock
Dec 10 2020	SELL Open market or private sale	$212,400 $70.8 p/Share	3,000 Reduced 10.71%	25,000 Common Stock

Also insider at

PTGX

Protagonist Therapeutics, Inc Healthcare

Director

ANNX

Annexon, Inc. Healthcare

TSBX

Turnstone Biologics Corp.

WDW